Skyline Therapeutics Receives FDA Clearance of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration.

Keywords: Age-Related Macular Degeneration; Bioengineering; Biotechnology; Clinical Research; Clinical Trials and Studies; Drugs and Therapies; Eye Diseases and Conditions; Gene Therapy; Genetics; Government Agencies Offices and Entities; Health and Medicine; Macular Degeneration; Pharmaceuticals; Post-Trial Research; Pre-Trial Research; Retinal Degeneration; Retinal Diseases and Conditions; Skyline Therapeutics; Therapy EN Age-Related Macular Degeneration Bioengineering Biotechnology Clinical Research Clinical Trials and Studies Drugs and Therapies Eye Diseases and Conditions Gene Therapy Genetics Government Agencies Offices and Entities Health and Medicine Macular Degeneration Pharmaceuticals Post-Trial Research Pre-Trial Research Retinal Degeneration Retinal Diseases and Conditions Skyline Therapeutics Therapy 1316 1316 1 07/17/23 20230717 NES 230717 2023 JUL 17 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Skyline Therapeutics, an innovation-driven gene therapy company committed to developing unique and novel solutions for rare and severe diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Phase I/IIa clinical trial of SKG0106, a one-time intravitreally delivered AAV gene therapy for the treatment of neovascular age-related macular degeneration (nAMD). Keywords for this news article include: Biotechnology, Pharmaceuticals, Genetics, Gene Therapy, Bioengineering, Clinical Research, Pre-Trial Research, Drugs and Therapies, Health and Medicine, Post-Trial Research, Retinal Degeneration, Skyline Therapeutics, Clinical Trials and Studies, Eye Diseases and Conditions, Retinal Diseases and Conditions. [Extracted from the article]

Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)